健康元(600380) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 4,089,279,479.56, a decrease of 5.77% compared to CNY 4,339,814,452.16 in the same period last year[5] - Net profit attributable to shareholders was CNY 435,788,328.07, down 0.91% from CNY 439,798,106.55 year-on-year[5] - Total operating revenue for Q1 2025 was approximately ¥4.09 billion, a decrease of 5.76% compared to ¥4.34 billion in Q1 2024[20] - Net profit for Q1 2025 was approximately ¥961.12 million, an increase of 3.91% from ¥925.10 million in Q1 2024[20] - Total comprehensive income for Q1 2025 was approximately ¥943.23 million, compared to ¥902.55 million in Q1 2024, reflecting an increase of 4.51%[21] Cash Flow - The net cash flow from operating activities decreased by 16.70% to CNY 809,939,509.20 from CNY 972,276,972.65 in the previous year[5] - Cash flow from operating activities for Q1 2025 was approximately ¥809.94 million, down from ¥972.28 million in Q1 2024, a decrease of 16.67%[23] - The company reported a net cash outflow from investment activities of CNY -260,760,843.96, a decrease compared to CNY -660,694,051.81 in the same period last year[10] - Net cash flow from investing activities was approximately -¥260.76 million in Q1 2025, an improvement from -¥660.69 million in Q1 2024[23] - Net cash flow from financing activities was approximately -¥514.55 million in Q1 2025, compared to -¥894.82 million in Q1 2024, indicating a reduction in cash outflow[23] Assets and Liabilities - The total assets at the end of the reporting period were CNY 35,768,906,356.14, reflecting a slight increase of 0.14% from CNY 35,718,129,456.13 at the end of the previous year[5] - The company's current assets totaled CNY 23,037,766,251.06, which is a marginal increase from CNY 23,005,860,977.31 in the previous period[17] - The total liabilities decreased to CNY 11,914,949,343.90 from CNY 12,317,986,676.85, indicating a reduction in financial obligations[18] - The company's equity increased to CNY 23,853,957,012.24 from CNY 23,400,142,779.28, reflecting a growth in shareholder value[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 79,702[12] - The largest shareholder, Shenzhen Baiye Yuan Investment Co., Ltd., held 48.96% of the shares, amounting to 895,653,653 shares[12] Operational Efficiency - The company experienced a 41.18% decrease in contract liabilities, amounting to CNY 83,757,675.11, as some pre-received contract payments were recognized as revenue[9] - The accounts receivable rose to CNY 2,590,448,694.38 from CNY 2,429,891,052.01, indicating improved credit sales[17] - The inventory decreased to CNY 2,484,790,118.05 from CNY 2,621,343,117.50, suggesting better inventory management[17] - Short-term borrowings were reported at CNY 2,325,000,000.00, down from CNY 2,455,000,000.00, reflecting a decrease in reliance on short-term debt[18] - The company reported a decrease in sales expenses to approximately ¥950.57 million in Q1 2025 from ¥1.10 billion in Q1 2024, a reduction of 13.43%[20] Research and Development - Research and development expenses decreased to approximately ¥300.36 million in Q1 2025 from ¥377.10 million in Q1 2024, a decline of 20.39%[20] Future Outlook - The company's net profit for the first quarter of 2025 will be detailed in the upcoming earnings report[19] - The company is focusing on expanding its market presence and enhancing product development strategies in the upcoming quarters[19]